Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Other

Alexander Pasternak

Lihu Yang

Haifeng Tang

Jinlong Jiang

Shawn P Walsh

Xin Gu

Changyou Zhou

Fa-Xiang Ding

Li Xiao

Barbara A Pio

Liangqin Guo

Sander G Mills

Yongxin Han

Gabor Butora

Shuwen He

Zhi-Cai Shi

Arthur A Patchett

Xianhai Huang

Jack D Scott

Hongjun Zhang

Dooseop Kim

Gregori J Morriello

Frank W Bennett

Wensheng Yu

Zhicai Wu

Guoqing Li

Harry R Chobanian

Joseph P Vacca

Joseph A Kozlowski

David L Sloman

Kevin Tyler Chapman

James R Tata

Ian W Davies

Hua Zhou

Xu Zhang

John Howard Hutchinson

Tesfaye Biftu

William K Hagmann

Ravi P Nargund

William H Parsons

Jean-Michel Andre Vernier

Paul E Finke

Jongwon Lim

Dong Xiao

David B Johnston

Steven P Govek

Theodore M Kamenecka

Derun Li

Helen Y Chen

Nunzio Sciammetta

Shuzhi Dong

Jessica Frie

Stephen D Goble

Aurash Shahripour

Takao Suzuki

Dane James Clausen

Brian Cato

Xavier Fradera

Haiqun Tang

Dexi Yang

Zhiqiang Zhao

Christopher Richard Moyes

Yuhua Huang

Qinghong Fu

Jianmin Fu

Ping Chen

Feng Ye

Katherine Young

Deodialsingh Guiadeen

Shankaran Kothandaraman

Yan Guo

Scott C Berk

Wanying Sun

Timothy A Blizzard

Yuping Zhu

Zhibo Zhang

Yang Yu

Kevin Michael Belyk

Qinglin Pu

Weidong Pan

Timothy Allen Blizzard

Rui Zhang

Jing Su

Weiguo Liu

Essa H Hu

Min K Park

Jianping Pan

Min Lu

David Jonathan Bennett

Celine Bonnefous

Mihir Mandal

Meng Hsin Chen

Yi Zang

Zhiqiang Guo

Shu-Wei Yang

Ming Wang

Indu T Bharathan

Kothandaraman Shankaran

Yunfeng Bai

Zhixiang Zheng

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors

Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Formula (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

[1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

The present invention relates to monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof. The present invention also relates to compositions which comprise a monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic. 

Chromane monobactam compounds for the treatment of bacterial infections

Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

[3.3.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors

The present invention relates to metallo-&#x3b2;-lactamase inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Z, R, X, Xand Rare as defined herein. The present invention also relates to compositions which comprise a metallo-&#x3b2;-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more &#x3b2;-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance. 

Metallo-beta-lactamase inhibitors and methods of use thereof

The present invention relates to metallo-&#x3b2;-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, R, X, Xand Rare as defined herein. The present invention also relates to compositions which comprise a metallo-&#x3b2;-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more &#x3b2;-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

Metallo-beta-lactamase inhibitors

The present invention relates to metallo-&#x3b2;-lactamase inhibitor compounds of Formula I: (I) and pharmaceutically acceptable salts thereof, wherein Z, R, X, Xand Rare as defined herein. The present invention also relates to compositions which comprise a metallo-&#x3b2;-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more &#x3b2;-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance. 

Metallo-&#x3b2;-lactamase inhibitors

The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, R, X, Xand Rare as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more &#x3b2;-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance. 

The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. 

Inhibitors of the renal outer medullary potassium channel

The present invention provides compounds of Formula (I); and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. 

Growing community of inventors

Princeton, NJ, United States of America

Alexander Pasternak